Vanguard disaggregates holdings after internal realignment (ABBV)
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting 0% ownership of AbbVie Inc. The filing states an 0 amount of common shares beneficially owned and shows 0% of the class. The filing explains an internal realignment completed January 12, 2026 that caused certain Vanguard subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Positive
- None.
Negative
- None.
Insights
Amendment shows disaggregated reporting after Vanguard realignment; no beneficial ownership in AbbVie is reported.
The Vanguard Group reports an 0 share position and 0% ownership of AbbVie common stock in this Amendment No. 12 filing. The filing attributes the change to an internal realignment effective January 12, 2026 and cites SEC Release No. 34-39538 (January 12, 1998) as the basis for disaggregated reporting by subsidiaries or business divisions.
Cash‑flow treatment and trading activity are not disclosed in the excerpt; future holdings by individual Vanguard entities will appear in separate 13G/A filings under the referenced Release. Subsequent filings from Vanguard entities may show any active positions.
FAQ
What does Vanguard report for ABBV ownership in this Schedule 13G/A amendment?
Why did Vanguard change its ownership reporting for ABBV?
Who signed the Schedule 13G/A amendment for Vanguard (ABBV)?
Does this amendment show any shares held by Vanguard subsidiaries for ABBV?